Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sirpiglenastat - Dracen Pharmaceuticals

Next Previous
Drug Profile

Sirpiglenastat - Dracen Pharmaceuticals

Alternative Names: DRP 104

Latest Information Update: 03 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Institute of Organic Chemistry and Biochemistry (Prague); Johns Hopkins University
  • Developer Dracen Pharmaceuticals; Johns Hopkins University
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Glutamine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I/II Liver cancer; Solid tumours

Most Recent Events

  • 01 Dec 2025 Phase-II clinical trials in Non-small cell lung cancer (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA (SC) (NCT07249372)
  • 06 Feb 2024 Phase-I/II clinical trials in Liver cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater, In adolescents, In adults, In the elderly) in USA (SC) (NCT06027086)
  • 09 Oct 2023 Pharmacodynamics data from a preclinical trial in Pancreatic cancer released by Dracen Pharmaceuticals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top